Tumor-specific hyperactive low-molecular-weight cyclin E isoforms detection and characterization in non-metastatic colorectal tumors

Cancer Biology and Therapy

Volumn 5, Issue 2, 2006, Pages 198-203

  Corin, Irina ^a   Di Giacomo, Marilena C ^b   Lastella, Patrizia ^b   Bagnulo, Rosanna ^b   Guanti, Ginevra ^b   Simone, Cristiano ^b,c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF BARI   (Italy)

^c Temple University   (United States)

Author keywords

Colorectal cancer; Cyclin E low molecular weight isoforms; Genomic instability; p53; Tumor markers

Indexed keywords

APC PROTEIN; CYCLIN E; DNA; PROTEIN P53;

ANTIGEN DETECTION; ARTICLE; CANCER CELL; CHROMOSOMAL INSTABILITY; COLORECTAL TUMOR; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; GENOMIC INSTABILITY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROSATELLITE INSTABILITY; MOLECULAR WEIGHT; MUTATION; PROGNOSIS;

EID: 33644646502     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.2.2356     Document Type: Article

References (38)

1. Moroy T, Geisen C. Cyclin E. Int J Biochem Cell Biol 2004; 36:1424-39.
2. Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, Rideout WM, Bronson RT, Gardner H, Sicinski P. Cyclin E ablation in the mouse. Cell 2003; 114:431-43.
3. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386:623-7.
4. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: The syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995; 87:1114-25.
5. Simone C, Resta N, Bagella L, Giordano A, Guanti G. Cyclin E and chromosome instability in colorectal cancer cell lines. Mol Pathol 2002a; 55:200-3.
6. Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004; 428:77-81.
7. Sutter T, Dansranjavin T, Lubinski J, Debniak T, Giannakudis J, Hoang-Vu C, Dralle H. Overexpression of cyclin E protein is closely related to the mutator phenotype of colorectal carcinoma. Int J Colorectal Dis 2002; 17:374-80.
8. Yasui W, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E. Expression of cyclin E in colorectal adenomas and adenocarcinomas: Correlation with expression of Ki-67 antigen and p53 protein. Virchows Arch 1996; 429:13-9.
9. Kitahara K, Yasui W, Kuniyasu H, Yokozaki H, Akama Y, Yunotani S, Hisatsugu T, Tahara E. Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int J Cancer 1995; 62:25-8.
10. Yasui W, Fujimoto J, Suzuki T, Ono S, Naka K, Yokozaki H, Tahara E. Expression of cell-cycle-regulating transcription factor E2F-1 in colorectal carcinomas. Pathobiology 1999; 67:174-9.
11. Weinert T. DNA damage and checkpoint pathways: Molecular anatomy and interactions with repair. Cell 1998; 94:555-8.
12. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25.
13. Kimura T, Gotoh M, Nakamura Y, Arakawa H. hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci 2003; 94:431-6.
14. Minella AC, Swanger J, Bryant E, Welcker M, Hwang H, Clurman BE. p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol 2002; 12:1817-27.
15. Kawamura K, Izumi H, Ma Z, Ikeda R, Moriyama M, Tanaka T, Nojima T, Levin LS, Fujikawa-Yamamoto K, Suzuki K, Fukasawa K. Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression. Cancer Res 2004; 64:4800-9.
16. Akli S, Keyomarsi K. Low-molecular-weight cyclin E: The missing link between biology and clinical outcome. Breast Cancer Res 2004; 6:188-91.
17. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347:1566-75.
18. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 2004; 23:2648-57.
19. Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, Reed JA, Timchenko N, van den Oord JJ, Bar-Eli M, Keyomarsi K, Medrano EE. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 2005; 65:692-7.
20. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, Keyomarsi K. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001; 21:6254-69.
21. Harwell RM, Mull BB, Porter DC, Keyomarsi K. Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells. J Biol Chem 2004; 279:12695-705.
22. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004; 64:3198-208.
23. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 2005; 280:15148-57.
24. Guanti G, Resta N, Simone C, Cariola F, Demma I, Fiorente P, Gentile M. Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis. Hum Mol Genet 2000; 9:283-7.
25. Iacopetta B. TP53 mutations in colorectal cancer. Hum Mutat 2003; 21:271-6.
26. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, Aoki T, Mild Y, Mori, Nakamura Y. Somatic mutations of the APC gene in colorectal tumors: Mutation cluster region in the APC gene. Hum Mol Genet 1992; 1:229-33.
27. Resta N, Simone C, Mareni C, Montera M, Gentile M, Susca F, Gristina R, Pozzi S, Bertario L, Bufo P, Carlomagno N, Ingrosso M, Rossini FP, Tenconi R, Guanti G. STK11 mutations in Peutz-Jeghers syndrome and sporadic colon cancer. Cancer Res 1998; 58:4799-801.
28. Keyomarsi K, Conte Jr D, Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene 1995; 11:941-50.
29. Simone C, Bagella L, Bellan C, Giordano A. Physical interaction between pRb and cdk9/cyclinT2 complex. Oncogene 2002c; 21:4158-65.
30. Simone C, Stiegler P, Bagella L, Pucci B, Bellan C, De Falco G, De Luca A, Guanti G, Puri PL, Giordano A. Activation of MyoD-dependent transcription by cdk9/cyclin T2. Oncogene 2002b; 21:4137-48.
31. Chang DK, Goel A, Ricciardiello L, Lee DH, Chang CL, Carethers JM, Boland CR. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines. Cancer Lett 2003; 195:243-51.
32. Chang SC, Lin JK, Lin TC, Liang WY. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol 2005; 26:65-75.
33. Weinstein IB. Disorders in cell circuitry during multistage carcinogenesis: The role of homeostasis. Carcinogenesis 2000; 21:857-64.
34. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413:316-22.
35. Welcker M, Singer J, Loeb KR, Grim J, Bloecher A, Gurien-West M, Clurman BE, Roberts JM. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell 2003; 12:381-92.
36. Schulman BA, Lindstrom DL, Harlow E. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc Natl Acad Sci USA 1998; 95:10453-8.
37. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996; 382:325-31.
38. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-70.